Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Ascendis Pharma A/S $ASND

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,866 shares of the biotechnology company’s stock, valued at approximately $2,317,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Rhumbline Advisers lifted its position in Ascendis Pharma A/S by 4.0% in the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after buying an additional 55 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Ascendis Pharma A/S by 1.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock worth $1,209,000 after buying an additional 58 shares during the last quarter. Certuity LLC lifted its position in Ascendis Pharma A/S by 5.7% in the fourth quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock worth $249,000 after buying an additional 63 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Ascendis Pharma A/S by 15.1% in the fourth quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $117,000 after buying an additional 72 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its position in Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after buying an additional 83 shares during the last quarter.

Ascendis Pharma A/S Trading Up 1.4%

ASND stock opened at $241.34 on Thursday. The company has a market capitalization of $15.05 billion, a PE ratio of 27.84 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $153.49 and a 12 month high of $250.74. The firm’s 50-day moving average is $232.15 and its 200 day moving average is $221.32. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. On average, research analysts anticipate that Ascendis Pharma A/S will post 12.19 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $300.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Stifel Nicolaus set a $332.00 price target on Ascendis Pharma A/S in a research report on Wednesday, March 4th. Oppenheimer raised their price target on Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Bank of America raised their price target on Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $295.39.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, insider Flemming Steen Jensen sold 19,460 shares of Ascendis Pharma A/S stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 40.00% of the stock is owned by insiders.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.